Related Experiment Videos
Thrombolytic therapy in review
S H Thomas1, S M Shepherd, E J Allison
1Department of Emergency Medicine, East Carolina University School of Medicine/University Medical Center of Eastern Carolina, Greenville, North Carolina 27858-4354.
Insights
Thrombolytic agents are increasingly used for various conditions, but optimal use and agent selection remain debated. This review covers current thrombolytic therapy for heart attacks, pulmonary embolism, and strokes.
Area of Science:
- Cardiology
- Vascular Medicine
- Neurology
Background:
- Thrombolytic therapy is a rapidly advancing field with ongoing debate regarding its optimal application.
- Recent research focuses on comparing different thrombolytic agents and dosing strategies to maximize benefits and minimize risks.
Purpose of the Study:
- To review the current status of thrombolytic therapy for major cardiovascular and cerebrovascular diseases.
- To discuss the benefits and risks associated with thrombolytic agents in specific clinical scenarios.
Main Methods:
- Literature review of recent studies on thrombolytic agents.
- Analysis of therapeutic outcomes and risk profiles for different indications.
- Synthesis of current evidence for coronary artery disease, pulmonary embolism, peripheral vascular thrombosis, and cerebrovascular infarction.
Main Results:
- Thrombolytic therapy is established for acute coronary syndromes and pulmonary embolism.
- Evidence for peripheral vascular thrombosis and cerebrovascular infarction is more variable and debated.
- Different agents and regimens show varying efficacy and safety profiles.
Conclusions:
- Thrombolytic therapy offers significant benefits in specific thrombotic conditions.
- Careful selection of agents and dosing is crucial for optimal patient outcomes.
- Further research is needed to refine treatment protocols for all indications.
Abstract:
The use of thrombolytic agents for both coronary and noncoronary indications is a rapidly progressing field. There has been substantial debate over which disease processes ultimately benefit from the use of thrombolytic agents. In addition, many recent studies have focused on comparing different thrombolytic agents and dosing regimens in an attempt to gain optimal therapeutic benefit with minimal risk. This paper discusses the current status of thrombolytic therapy for coronary artery disease, pulmonary embolus, peripheral vascular thrombosis, and cerebrovascular infarction.